Genomic Valley Biotech Intrinsic Value
Genomic Valley Biotech (GVBL) median intrinsic value is ₹26.67 from 2 valuation models (range ₹8–₹27), vs current price ₹26.67 — 0.0% downside (Trading Near Calculated Value). For current market price and key ratios, visit Genomic Valley Biotech stock price NSE.
GVBL Valuation Methods Summary — DCF, Graham Number & P/E
Genomic Valley Biotech intrinsic value across 2 models vs current price ₹26.67 — upside/downside and value range per method. Browse GVBL income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹26.67 | ₹24.00 - ₹29.34 | 0.0% | Book Value/Share: ₹13.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹8.00 | ₹7.20 - ₹8.80 | -70.0% | Revenue/Share: ₹3.33, P/S: 2.0x |
GVBL Intrinsic Value vs Market Price — All Valuation Models
Genomic Valley Biotech fair value range ₹8–₹27 vs current market price ₹26.67 across 2 valuation models. Also explore Genomic Valley Biotech stock price data download to track price trends across different timeframes.
GVBL Intrinsic Value Analysis — Undervalued or Overvalued?
Genomic Valley Biotech median intrinsic value ₹26.67, current price ₹26.67 — Trading Near Calculated Value by 0.0%.
What is the intrinsic value of GVBL?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Genomic Valley Biotech (GVBL) is ₹26.67 (median value). With the current market price of ₹26.67, this represents a 0.0% variance from our estimated fair value.
The valuation range spans from ₹8.00 to ₹26.67, indicating ₹8.00 - ₹26.67.
Is GVBL undervalued or overvalued?
Based on our multi-method analysis, Genomic Valley Biotech (GVBL) appears to be trading near calculated value by approximately 0.0%.
GVBL Financial Health — Key Ratios vs Industry Benchmarks
Genomic Valley Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.25x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
GVBL Cash Flow Quality — Operating & Free Cash Flow
Genomic Valley Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |